Johnson & Johnson's ($JNJ) Janssen Biotech unit has made a big deal with the small biotech Pharmacyclics. Janssen will pay $150 million up front--and $975 million total, if milestones are met--for a midstage blood-cancer treatment. Report
Phase 2 is the end of the road for many molecules and for others the source of later delays and denials. Learn techniques for mitigating the risks that threaten your development program in the new white paper, Mitigating Phase 2 Development Risks: Design and Operational Strategies and Case Studies for Phase 2 Success. Download the white paper today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!